2022 / 01

Next Paper
DOI: 10.24075/brsmu.2022.004

ORIGINAL RESEARCH

Microsatellite instability in colorectal neuroendocrine neoplasms

Meshcheryakova MYu, Kolesnikov EN, Trifanov VS, Timoshkina NN, Snezhko AV, Gvaldin DYu
About authors

National Medical Research Center of Oncology, Rostov-on-Don, Russia

Correspondence should be addressed: Milana Yu. Mesheryakova
14 liniya, 63, Rostov-on-Don; ur.liam@analimavokayrehsem

About paper

Author contributions: Kolesnikov EN — data collection, analysis and interpretation; manuscript editing; Trifanov VS — study design; data collection, manuscript editing; Timoshkina NN — data analysis and interpretation; manuscript preparation; Snezhko AV — data acquisition; Gvaldin DYu — data analysis and interpretation; Meshcheryakova MYu — literature analysis; manuscript preparation.

Compliance with ethical standards: the study was approved by the Ethics Committee of the National Medical Research Centre for Oncology (Protocol № 3 dated February 9, 2021); informed consent was obtained from all study participants.

Received: 2022-01-12 Accepted: 2022-01-27 Published online: 2022-02-14
|
  1. Ratovomanana T, Cohen R, Svrcek M, Renaud F, Cervera P, Siret A, et al. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair. Gastroenterology. 2021; 161 (3): 814–26.
  2. Echle A, Grabsch HI, Quirke P, van den Brandt PA, West NP, Hutchins GGA, et al. Clinical-Grade Detection of Microsatellite Instability in Colorectal Tumors by Deep Learning. Gastroenterology. 2020; 159 (4): 1406–16.
  3. Andre T, Amonkar M, Norquist JM, Shiu KK, Kim TW, Jensen BV, et al. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021; 22 (5): 665–77.
  4. Diao Z, Han Y, Chen Y, Zhang R, Li J. The clinical utility of microsatellite instability in colorectal cancer. Crit Rev Oncol Hematol. 2021; 157 (1): 103–71.
  5. Trjakin AA, Fedjanin MYu, Cukanov AS, Shelygin YuA, Pokataev IA, Ignatova EO, i dr. Mikrosatellitnaja nestabil'nost' kak unikal'naja harakteristika opuholei i prediktor jeffektivnosti immunoterapii. ̆ Zlokachestvennye opuholi. 2019; 9 (4): 59–69. Russian.
  6. Sahnane N, Furlan D, Monti M, Romualdi C, Vanoli A, Vicari E, et al. Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity. Endocr Relat Cancer. 2015; 22 (1): 35–45.
  7. Musaeljan AA, Nazarov VD, Budnikova AS, Lapin SV, Vorobev SL, Jemanujel VL, i dr. Kliniko-morfologicheskij portret opuholej s mikrosatellitnoj nestabil'nost'ju. Uspehi molekuljarnoj onkologii. 2021; 8 (2): 52–59. Russian.
  8. Trifanov VS, Timoshkina NN, Gvaldin DYu, Mesheryakova MYu, Kolesnikov EN, Gaziev UM, et al. Study of microsatellite instability in neuroendocrine tumors of pancreas and colon. Journal of Clinical Oncology. 2021; 39 (15): 16196.
  9. Fraune C, Simon R, Hube-Magg C, Makrypidi-Fraune G, Kluth M, Büscheck F, et al. Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas. Endocr Pathol. 2020; 31 (2): 182–9.
  10. Xing J, Ying H, Li J, Gao Y, Sun Z, Li J, et al. Immune Checkpoint Markers in Neuroendocrine Carcinoma of the Digestive System. Front Oncol. 2020; 28 (10): 132.
  11. Girardi DM, Silva ACB, Rêgo JFM, Coudry RA, Riechelmann RP. Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review. Cancer Treat Rev. 2017; 56 (1): 28–35.
  12. Mitsuhashi K, Yamamoto I, Kurihara H, Kanno S, Ito M, Igarashi H, et al. Analysis of the molecular features of rectal carcinoid tumors to identify new biomarkers that predict biological malignancy. Oncotarget. 2015; 6 (26): 22114–25.
  13. Kidd M, Eick G, Shapiro MD, Camp RL, Mane SM, Modlin IM. Microsatellite instability and gene mutations in transforming growth factor-beta type II receptor are absent in small bowel carcinoid tumors. Cancer. 2005; 103 (2): 229–36.
  14. Ghimenti C, Lonobile A, Campani D, Bevilacqua G, Caligo MA. Microsatellite instability and allelic losses in neuroendocrine tumors of the gastro-entero-pancreatic system. Int J Oncol. 1999; 15 (2): 361–6.
  15. Arnold CN, Nagasaka T, Goel A, Scharf I, Grabowski P, Sosnowski A, et al. Molecular characteristics and predictors of survival in patients with malignant neuroendocrine tumors. Int J Cancer. 2008; 123 (7): 1556–64.
  16. Dudley JC, Lin MT, Le DT, Eshleman JR. Microsatellite Instability as a Biomarker for PD-1 Blockade. Clin Cancer Res. 2016; 22 (4): 813–20.
  17. Olevian DC, Nikiforova MN, Chiosea S, Sun W, Bahary N, Kuan SF, et al. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival. Hum Pathol. 2016; 49 (1): 124–34.
  18. Furlan D, Sahnane N, Mazzoni M, Pastorino R, Carnevali I, Stefanoli M, et al. Diagnostic utility of MS-MLPA in DNA methylation profiling of adenocarcinomas and neuroendocrine carcinomas of the colonrectum. Virchows Arch. 2013; 462 (1): 47–56.
  19. La Rosa S, Marando A, Furlan D, Sahnane N, Capella C. Colorectal poorly differentiated neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas: insights into the diagnostic immunophenotype, assessment of methylation profile, and search for prognostic markers. Am J Surg Pathol. 2012; 36 (4): 601–11.
  20. Kit OI, Trifanov VS, Petrusenko NA, Gvaldin DY, Kutilin DS, Timoshkina NN. Identification of new candidate genes and signalling pathways associated with the development of neuroendocrine pancreatic tumours based on next generation sequencing data. Mol Biol Rep. 2020; 47 (6): 4233–43.
  21. Kit OI, Vodolazhskij DI. Molekuljarnaja biologija kolorektal'nogo raka v klinicheskoj praktike. Molekuljarnaja biologija. 2015; 49 (4): 531–54. Russian.